Fosamax Prescribing for a 78-Year-Old White Female with Osteopenia
For a 78-year-old woman with osteopenia (not osteoporosis), Fosamax should NOT be routinely prescribed without first assessing her individualized fracture risk using FRAX or similar tools, as treatment decisions in osteopenia require balancing potential benefits against harms based on absolute fracture risk.
Risk Assessment Required Before Treatment
The critical distinction here is osteopenia versus osteoporosis. Current guidelines emphasize that osteopenia alone (T-score between -1.0 and -2.5) does not automatically warrant bisphosphonate therapy 1, 2, 3.
Key decision points:
- Calculate 10-year fracture risk using FRAX or similar validated tools
- Treatment threshold: Consider pharmacologic therapy if 10-year risk of major osteoporotic fracture ≥20% OR hip fracture risk ≥3% 1
- The American College of Physicians recommends an individualized approach for women over 65 with osteopenia, weighing patient preferences, fracture risk profile, benefits, harms, and costs 2, 3
If Treatment Is Indicated
Should treatment be warranted based on high fracture risk assessment, the standard Fosamax regimen is:
- Alendronate 70 mg once weekly 4, 5
- Combined with calcium 1200 mg daily (from all sources) and vitamin D 800-1000 IU daily 6
Critical Administration Instructions
The patient must follow these strict dosing requirements to ensure efficacy and minimize esophageal complications 4, 5:
- Take upon arising for the day, at least 30 minutes before first food, beverage, or other medication
- Swallow with a full glass (6-8 oz) of plain water only
- Remain upright (sitting or standing) for at least 30 minutes after taking
- Do not take at bedtime
Contraindications and Precautions
Do not prescribe if the patient has 4:
- Creatinine clearance <35 mL/min
- Active esophageal disease or inability to remain upright for 30 minutes
- Hypocalcemia (must be corrected first)
- Esophageal abnormalities (achalasia, stricture, dysmotility)
Before initiating therapy 6, 7, 6:
- Check serum calcium, 25-OH vitamin D, and consider parathyroid hormone
- Correct vitamin D deficiency BEFORE starting bisphosphonates (target 25-OH vitamin D >30 ng/mL, ideally 40-50 ng/mL)
- Complete any necessary dental work, as osteonecrosis of the jaw risk increases with duration of therapy (though rare at osteoporosis doses: <1 per 10,000-100,000 person-years) 6, 7
Treatment Duration and Monitoring
Treatment duration recommendations 4, 2, 8, 9:
- Initial treatment period: 3-5 years
- After 5 years of oral bisphosphonate therapy, reassess fracture risk
- For patients at continued high risk (very low T-scores, prior major fractures, advanced age), consider continuation up to 10 years
- For lower-risk patients after 5 years, consider a "drug holiday" of 2-3 years with periodic fracture risk reassessment
Monitoring during treatment:
- The American College of Physicians recommends AGAINST routine BMD monitoring during the initial 5-year treatment period 2
- Reassess fracture risk at 2-4 year intervals if on drug holiday 4
Important Clinical Caveats
Age considerations: At 78 years old, this patient is at higher baseline fracture risk simply due to age. However, osteopenia alone does not equal treatment indication. The evidence for bisphosphonates reducing fractures in osteopenia is limited 2, 3. The strongest evidence supports treatment in women with osteoporosis (T-score ≤-2.5) or those with osteopenia plus high calculated fracture risk 1, 2.
Alternative if osteoporosis confirmed: If repeat DXA shows osteoporosis (T-score ≤-2.5), then alendronate becomes a strong first-line recommendation with high-quality evidence for reducing hip and vertebral fractures 4, 2.
Vitamin D supplementation: Given her age >70 years, she likely needs additional vitamin D beyond the combination product. The Fosamax Plus D formulation (70 mg alendronate/5600 IU vitamin D3 weekly) provides 800 IU daily equivalent, which may be appropriate 5. However, check her baseline 25-OH vitamin D level first 6.
Common pitfall: Do not automatically prescribe bisphosphonates for osteopenia without fracture risk assessment. This represents overtreatment in many cases and exposes patients to unnecessary medication risks, costs, and potential long-term complications like atypical femoral fractures (which increase with treatment duration) 9.